Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Intuitive Surgical Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The analysis of short-term operating activity reveals a significant lengthening of the operational cycle, primarily driven by a decline in inventory efficiency. While receivables management remains stable, the overall cash conversion cycle has trended upward over the observed period.
- Inventory Management
- A consistent downward trend in inventory turnover is observed, declining from 2.82 in March 2022 to 1.81 by June 2026. This decline is mirrored by a substantial increase in the average inventory processing period, which expanded from 130 days to 201 days. This pattern suggests a slower movement of goods or a strategic increase in safety stock levels, effectively tying up more capital in inventory.
- Receivables Efficiency
- Receivables turnover has remained relatively stable, generally fluctuating between 6.30 and 7.63. The average receivable collection period shows minimal volatility, consistently ranging between 48 and 58 days. This indicates a disciplined and predictable credit collection process that has not been adversely affected by the changes in inventory velocity.
- Payables and Liquidity
- The payables turnover ratio exhibits periodic fluctuations, with the average payables payment period typically remaining between 25 and 35 days. The lack of a significant long-term increase in the payment period suggests that the company is not relying on extending supplier credit to offset the slowdown in inventory turnover.
- Operating and Cash Conversion Cycles
- The operating cycle has experienced a marked increase, rising from 186 days in March 2022 to 256 days by June 2026. Consequently, the cash conversion cycle has lengthened from 161 days to 228 days. This indicates that the time required to convert resource inputs into cash has increased by approximately 67 days, primarily due to the expanded inventory processing timeline.
- Working Capital Utilization
- Working capital turnover initially showed a downward trend, hitting a low of 0.95 in September 2023, but has since recovered to 1.45 by June 2026. This recovery suggests an improvement in the efficiency with which working capital is utilized to generate sales, despite the prolonged cash conversion cycle.
AI Ask an analyst for more
Turnover Ratios
Average No. Days
Inventory Turnover
Intuitive Surgical Inc., inventory turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Cost of revenue | 931,900) | 940,300) | 961,900) | 842,700) | 822,100) | 795,700) | 771,300) | 664,200) | 637,200) | 645,200) | 650,900) | 576,500) | 584,000) | 583,200) | 544,100) | 505,300) | 498,800) | 478,000) | ||||||
| Inventory | 2,028,700) | 1,945,100) | 1,840,000) | 1,781,900) | 1,667,000) | 1,553,600) | 1,487,200) | 1,481,700) | 1,383,900) | 1,299,300) | 1,220,600) | 1,147,500) | 1,005,200) | 946,600) | 893,200) | 837,100) | 724,000) | 653,000) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Inventory turnover1 | 1.81 | 1.83 | 1.86 | 1.81 | 1.83 | 1.85 | 1.83 | 1.75 | 1.81 | 1.89 | 1.96 | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 2.76 | 2.82 | 2.98 | 2.88 | 2.73 | 2.82 | 3.02 | 2.69 | 2.67 | 2.65 | 2.74 | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | ||||||
| Medtronic PLC | 1.95 | 2.02 | 2.12 | 2.06 | 2.11 | 2.10 | 2.15 | 1.95 | 1.92 | 1.91 | 2.03 | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Inventory turnover
= (Cost of revenueQ2 2026
+ Cost of revenueQ1 2026
+ Cost of revenueQ4 2025
+ Cost of revenueQ3 2025)
÷ Inventory
= (931,900 + 940,300 + 961,900 + 842,700)
÷ 2,028,700 = 1.81
2 Click competitor name to see calculations.
An analysis of operating activity reveals a consistent decline in inventory turnover efficiency from early 2022 through mid-2024, followed by a period of stabilization. While the cost of revenue exhibits a steady upward trajectory, inventory levels have expanded at a significantly faster rate, leading to a reduction in the frequency with which inventory is cycled.
- Inventory Turnover Trend
- The inventory turnover ratio experienced a sustained decrease, falling from 2.82 in March 2022 to a low of 1.75 by September 2024. This represents a notable reduction in the efficiency of inventory conversion over the initial two-and-a-half-year period of the analyzed timeframe.
- Disproportionate Asset Accumulation
- Cost of revenue grew from 478,000 thousand US$ in March 2022 to 931,900 thousand US$ by June 2026. During the same period, inventory increased from 653,000 thousand US$ to 2,028,700 thousand US$. The inventory balance grew by approximately 211%, whereas the cost of revenue grew by approximately 95%, which directly accounts for the contraction in the turnover ratio.
- Operational Stabilization
- Beginning in late 2024, the inventory turnover ratio ceased its downward trajectory and entered a phase of relative stability. From December 2024 through June 2026, the ratio fluctuated within a narrow corridor between 1.81 and 1.86, suggesting that the rate of inventory accumulation has begun to align more closely with the growth in the cost of revenue.
AI Ask an analyst for more
Receivables Turnover
Intuitive Surgical Inc., receivables turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Revenue | 2,892,300) | 2,770,800) | 2,866,200) | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | ||||||
| Accounts receivable, net | 1,673,200) | 1,595,600) | 1,527,300) | 1,259,700) | 1,269,200) | 1,221,500) | 1,225,400) | 1,153,000) | 1,109,100) | 1,127,900) | 1,130,200) | 962,700) | 904,200) | 925,300) | 942,100) | 849,600) | 838,500) | 906,100) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Receivables turnover1 | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 5.42 | 5.50 | 5.59 | 5.39 | 5.41 | 5.78 | 6.06 | 5.85 | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | ||||||
| Elevance Health Inc. | 14.99 | 14.30 | 16.34 | 16.80 | 14.83 | 14.42 | 18.00 | 19.84 | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | ||||||
| Medtronic PLC | 5.44 | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | ||||||
| UnitedHealth Group Inc. | — | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Receivables turnover
= (RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025)
÷ Accounts receivable, net
= (2,892,300 + 2,770,800 + 2,866,200 + 2,505,100)
÷ 1,673,200 = 6.59
2 Click competitor name to see calculations.
An analysis of operating activity from March 2022 through June 2026 reveals a consistent upward trajectory in both revenue and net accounts receivable. Revenue increased from 1.49 billion to 2.89 billion, while net accounts receivable grew from 906.1 million to 1.67 billion over the same period.
- Receivables Turnover Stability
- The receivables turnover ratio demonstrates a general state of stability, fluctuating within a range of 6.30 to 7.63. This indicates that the company has effectively scaled its collection processes to match its revenue growth, preventing a significant deterioration in credit quality or collection efficiency as the volume of business expanded.
- Cyclical Patterns
- A recurring trend of contraction in the turnover ratio is observed during the fourth quarter (December) of 2022, 2023, and 2025. These periodic declines suggest a seasonal accumulation of receivables at year-end, which are typically resolved in the subsequent first and second quarters.
- Efficiency Peaks and Troughs
- The highest efficiency in receivables management was recorded in September 2025, with a turnover ratio of 7.63. Conversely, the lowest efficiency occurred in December 2023, with a ratio of 6.30. Despite these variances, the ratio returned to a baseline of approximately 6.59 by June 2026, suggesting a sustainable equilibrium in the company's short-term operating cycle.
- Revenue and Receivable Correlation
- The correlation between revenue growth and the growth of net accounts receivable remains proportional. Although receivables surged significantly toward the end of 2025 and into 2026, the turnover ratio did not collapse, confirming that the increase in outstanding receivables is driven by higher sales volumes rather than a decline in payment velocity.
AI Ask an analyst for more
Payables Turnover
Intuitive Surgical Inc., payables turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Cost of revenue | 931,900) | 940,300) | 961,900) | 842,700) | 822,100) | 795,700) | 771,300) | 664,200) | 637,200) | 645,200) | 650,900) | 576,500) | 584,000) | 583,200) | 544,100) | 505,300) | 498,800) | 478,000) | ||||||
| Accounts payable | 277,200) | 332,900) | 255,100) | 291,200) | 266,800) | 276,200) | 193,400) | 218,700) | 194,400) | 194,400) | 188,700) | 196,200) | 199,700) | 164,100) | 147,000) | 164,200) | 149,700) | 128,100) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Payables turnover1 | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 4.22 | 4.22 | 4.56 | 4.69 | 4.40 | 4.44 | 4.46 | 4.54 | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | ||||||
| Elevance Health Inc. | 8.06 | 8.06 | 8.68 | 8.38 | 8.07 | 7.87 | 8.10 | 8.17 | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | ||||||
| Medtronic PLC | 4.64 | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | ||||||
| UnitedHealth Group Inc. | — | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Payables turnover
= (Cost of revenueQ2 2026
+ Cost of revenueQ1 2026
+ Cost of revenueQ4 2025
+ Cost of revenueQ3 2025)
÷ Accounts payable
= (931,900 + 940,300 + 961,900 + 842,700)
÷ 277,200 = 13.26
2 Click competitor name to see calculations.
A consistent upward trajectory is observed in the cost of revenue, which increased from 478,000 thousand US$ in March 2022 to 931,900 thousand US$ by June 2026. This growth indicates a significant expansion in operational scale and production volume over the analyzed period. Concurrently, accounts payable exhibited a general increase, rising from 128,100 thousand US$ to 277,200 thousand US$, although this growth was characterized by higher volatility than the cost of revenue.
- Payables Turnover Ratio Trends
- The payables turnover ratio fluctuated within a range of 10.39 to 14.36. A general downward shift is evident when comparing the early periods of the analysis to the later stages. The ratio reached its peak of 14.36 in March 2022 and saw several subsequent troughs, most notably in March 2025 (10.39) and March 2026 (10.71). This suggests a deceleration in the frequency with which the company settles its obligations to suppliers.
- Operational Efficiency and Working Capital
- The decline in the turnover ratio indicates that accounts payable grew at a faster proportional rate than the cost of revenue during the latter half of the period. While cost of revenue nearly doubled, the periodic spikes in accounts payable—particularly in March 2025 and March 2026—contributed to a lower turnover ratio. This pattern may reflect a strategic shift toward extending payment terms with vendors or an increase in the volume of credit purchases to support operational growth.
- Cyclical Volatility
- Short-term volatility is observed in the turnover ratio, with frequent oscillations between quarters. For instance, the ratio rose to 14.05 in December 2024 before dropping sharply to 10.39 in March 2025. Such fluctuations suggest that payables management is subject to quarterly timing differences in settlement or seasonal procurement cycles rather than a linear trend.
AI Ask an analyst for more
Working Capital Turnover
Intuitive Surgical Inc., working capital turnover calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||
| Current assets | 9,542,700) | 8,809,500) | 9,779,500) | 8,525,300) | 8,745,900) | 7,657,800) | 7,111,000) | 7,215,600) | 7,654,300) | 7,632,700) | 7,888,000) | 8,902,900) | 8,031,800) | 6,877,000) | 6,253,000) | 6,293,100) | 6,292,500) | 5,803,200) | ||||||
| Less: Current liabilities | 1,922,900) | 1,911,000) | 2,006,200) | 1,803,200) | 1,692,600) | 1,538,100) | 1,745,300) | 1,676,800) | 1,487,500) | 1,375,100) | 1,658,700) | 1,676,400) | 1,538,400) | 1,307,400) | 1,422,100) | 1,233,400) | 1,175,000) | 1,112,200) | ||||||
| Working capital | 7,619,800) | 6,898,500) | 7,773,300) | 6,722,100) | 7,053,300) | 6,119,700) | 5,365,700) | 5,538,800) | 6,166,800) | 6,257,600) | 6,229,300) | 7,226,500) | 6,493,400) | 5,569,600) | 4,830,900) | 5,059,700) | 5,117,500) | 4,691,000) | ||||||
| Revenue | 2,892,300) | 2,770,800) | 2,866,200) | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Working capital turnover1 | 1.45 | 1.53 | 1.29 | 1.43 | 1.30 | 1.42 | 1.56 | 1.42 | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 6.95 | 6.33 | 4.67 | 4.27 | 3.91 | 4.17 | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | ||||||
| Elevance Health Inc. | 7.19 | 7.59 | 7.50 | 7.00 | 7.96 | 8.11 | 7.85 | 6.87 | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | ||||||
| Medtronic PLC | 2.47 | 2.92 | 3.07 | 3.11 | 3.22 | 2.79 | 2.90 | 2.54 | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | ||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Working capital turnover
= (RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025)
÷ Working capital
= (2,892,300 + 2,770,800 + 2,866,200 + 2,505,100)
÷ 7,619,800 = 1.45
2 Click competitor name to see calculations.
The analysis of operating activity ratios from March 2022 through June 2026 reveals a period of sustained revenue expansion accompanied by fluctuating levels of short-term capital investment.
- Revenue Trajectory
- Revenue exhibits a consistent and strong upward trend, increasing from 1.48 billion USD in March 2022 to 2.89 billion USD by June 2026. This growth is steady, with a notable acceleration beginning in late 2023 and continuing through the end of the analyzed period.
- Working Capital Trends
- Working capital demonstrates a general increase over the period, rising from 4.69 billion USD to a peak of 7.77 billion USD in December 2025. The growth in working capital is characterized by volatility, with significant increases observed in mid-2023 and late 2025, interspersed with periods of contraction, such as the dip seen in late 2023 and 2024.
- Working Capital Turnover Performance
- The working capital turnover ratio displays a cyclical pattern. A period of declining efficiency is observed between March 2022 and September 2023, with the ratio falling from 1.26 to a low of 0.95. This suggests that during this phase, the growth in working capital outpaced revenue generation. A recovery phase followed, with the ratio climbing to a peak of 1.56 in December 2024, indicating a marked improvement in operational efficiency. In the final quarters of the period, the ratio stabilized between 1.29 and 1.53, reflecting a more optimized relationship between short-term assets and revenue output.
Overall, the data indicates that while the scale of short-term operations has expanded, the organization successfully reversed a trend of declining efficiency in 2023, ultimately achieving a higher turnover rate by 2026 compared to the 2022-2023 baseline.
AI Ask an analyst for more
Average Inventory Processing Period
Intuitive Surgical Inc., average inventory processing period calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Inventory turnover | 1.81 | 1.83 | 1.86 | 1.81 | 1.83 | 1.85 | 1.83 | 1.75 | 1.81 | 1.89 | 1.96 | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | ||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average inventory processing period1 | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 132 | 129 | 123 | 127 | 134 | 130 | 121 | 136 | 136 | 138 | 133 | 135 | 139 | 132 | 118 | 108 | 113 | 109 | ||||||
| Medtronic PLC | 187 | 181 | 172 | 178 | 173 | 174 | 170 | 187 | 190 | 191 | 180 | 190 | 183 | 174 | 166 | 161 | 153 | 148 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.81 = 201
2 Click competitor name to see calculations.
The analyzed period reveals a significant deterioration in inventory efficiency, characterized by a steady decline in turnover rates and a corresponding extension of the average inventory processing period.
- Inventory Turnover Analysis
- A consistent downward trend is observed in the inventory turnover ratio, which decreased from 2.82 in March 2022 to a low of 1.75 by September 2024. This decline indicates a reduction in the frequency with which inventory is cycled through the business. Following this low point, the ratio entered a stabilization phase, fluctuating marginally between 1.81 and 1.86 from December 2024 through June 2026.
- Average Inventory Processing Period Trends
- The average inventory processing period exhibits a strong inverse relationship with the turnover ratio, increasing from 130 days in March 2022 to a peak of 208 days in September 2024. This represents a substantial increase in the time inventory remains on hand before being sold or utilized. Similar to the turnover ratio, this metric reached a plateau in the latter half of the period, settling into a range between 196 and 201 days from late 2024 through mid-2026.
- Comparative Operational Insight
- The shift from a 130-day processing cycle to a baseline of approximately 200 days suggests a fundamental change in working capital dynamics. The period of rapid decline between 2022 and 2024 has been replaced by a phase of relative stability, suggesting that the current higher level of inventory holding has become the operational norm for the company.
AI Ask an analyst for more
Average Receivable Collection Period
Intuitive Surgical Inc., average receivable collection period calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Receivables turnover | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average receivable collection period1 | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 67 | 66 | 65 | 68 | 67 | 63 | 60 | 62 | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | ||||||
| Elevance Health Inc. | 24 | 26 | 22 | 22 | 25 | 25 | 20 | 18 | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | ||||||
| Medtronic PLC | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | ||||||
| UnitedHealth Group Inc. | — | 22 | 19 | 19 | 21 | 24 | 21 | 19 | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.59 = 55
2 Click competitor name to see calculations.
The analysis of the short-term operating activity ratios reveals a consistent inverse correlation between the receivables turnover ratio and the average receivable collection period. The company maintains a relatively stable efficiency in converting receivables into cash, with periodic fluctuations that suggest a cyclical pattern in credit and collection activities.
- Receivables Turnover Trends
- The receivables turnover ratio fluctuated between a minimum of 6.30 in December 2023 and a peak of 7.63 in September 2025. A recurring pattern is observed where turnover typically improves during the second and third quarters of the year before experiencing a contraction in the fourth quarter. For instance, the ratio rose to 7.20 in September 2022 and 7.37 in June 2023, followed by declines to 6.60 and 6.30, respectively, by the end of those calendar years.
- Average Receivable Collection Period Analysis
- The collection period remained largely within a range of 48 to 58 days. The most efficient collection cycle was recorded on September 30, 2025, with a period of 48 days. Conversely, the longest collection period occurred on December 31, 2023, reaching 58 days. From March 2024 through June 2026, the collection period demonstrated increased stability, frequently oscillating between 51 and 55 days, indicating a consistent credit management policy.
- Cyclical Performance and Stability
- A distinct year-end expansion in the collection period is observable, with values typically peaking in December (55 days in 2022, 58 days in 2023, and 55 days in 2025). This suggests a seasonal trend in payment timing or billing cycles. Despite these fluctuations, the return to a baseline of approximately 51 to 56 days in the first quarter of each subsequent year indicates that the company successfully recovers these balances in a timely manner.
AI Ask an analyst for more
Operating Cycle
Intuitive Surgical Inc., operating cycle calculation (quarterly data)
No. days
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Average receivable collection period | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Operating cycle1 | 256 | 254 | 251 | 249 | 250 | 249 | 254 | 261 | 254 | 249 | 244 | 234 | 216 | 215 | 216 | 206 | 190 | 186 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 199 | 195 | 188 | 195 | 201 | 193 | 181 | 198 | 197 | 198 | 193 | 194 | 195 | 185 | 170 | 160 | 171 | 168 | ||||||
| Medtronic PLC | 254 | 248 | 243 | 245 | 242 | 241 | 239 | 254 | 258 | 258 | 250 | 260 | 250 | 236 | 230 | 224 | 216 | 211 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 201 + 55 = 256
2 Click competitor name to see calculations.
The operating cycle exhibits a pronounced upward trajectory over the analyzed period, increasing from 186 days in March 2022 to 256 days by June 2026. This expansion indicates a lengthening of the duration between the initial investment in inventory and the ultimate realization of cash from sales.
- Average Inventory Processing Period
- A significant and steady increase is observed from March 2022, when the period stood at 130 days, peaking at 208 days in September 2024. Following this peak, the metric entered a stabilization phase, fluctuating narrowly between 196 and 201 days through June 2026. This trend suggests a substantial increase in the time required to process and sell inventory, which became the primary driver of the overall operating cycle expansion.
- Average Receivable Collection Period
- The collection of receivables has remained relatively stable throughout the period, with values oscillating between a low of 48 days and a high of 58 days. The absence of a strong directional trend indicates that the efficiency of credit and collection processes has been maintained independently of the changes occurring in inventory management.
- Operating Cycle Synthesis
- The total operating cycle grew by 70 days between March 2022 and June 2026. Analysis of the components reveals that this growth is almost exclusively attributable to the Average Inventory Processing Period. While the receivable collection period remained consistent, the inventory processing period shifted from 130 to 201 days. The operating cycle reached a plateau after September 2024, mirroring the stabilization seen in inventory levels, and concluded at 256 days in the final quarter of the analysis.
AI Ask an analyst for more
Average Payables Payment Period
Intuitive Surgical Inc., average payables payment period calculation (quarterly data)
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Payables turnover | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||
| Average payables payment period1 | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 87 | 87 | 80 | 78 | 83 | 82 | 82 | 80 | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | ||||||
| Elevance Health Inc. | 45 | 45 | 42 | 44 | 45 | 46 | 45 | 45 | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | ||||||
| Medtronic PLC | 79 | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | ||||||
| UnitedHealth Group Inc. | — | 46 | 46 | 49 | 49 | 50 | 47 | 48 | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 13.26 = 28
2 Click competitor name to see calculations.
The analysis of the accounts payable activity reveals a fluctuating but relatively stable payment cycle over the period from March 2022 to June 2026. The average payables payment period consistently oscillates within a range of 25 to 35 days, indicating a controlled approach to managing short-term obligations to suppliers without exhibiting a definitive long-term upward or downward trend.
- Payables Turnover Dynamics
- The payables turnover ratio maintains an inverse correlation with the payment period, with values ranging from a peak of 14.36 in March 2022 to a low of 10.39 in March 2025. These fluctuations reflect periodic variations in the velocity of supplier payments, suggesting adjustments in procurement volumes or strategic timing of disbursements.
- Payment Period Volatility
- The payment period exhibits cyclical behavior, reaching its maximum duration of 35 days in March 2025 and its minimum of 25 days in March 2022. Notable peaks occurred in June 2023 (33 days) and March 2026 (34 days), while relative troughs were observed in December 2022 (26 days) and December 2024 (26 days). This pattern suggests that the duration of payables is managed flexibly rather than adhering to a strict, unchanging schedule.
- Operational Liquidity Interpretation
- The consistency of the payment window, which remains largely confined between 25 and 35 days, indicates a stable relationship with vendors and a disciplined approach to working capital management. The absence of a sustained increase in the payment period suggests that the organization is not utilizing supplier credit as a primary means of financing operational growth, while the lack of a significant decrease suggests an efficient use of available cash flow.
AI Ask an analyst for more
Cash Conversion Cycle
Intuitive Surgical Inc., cash conversion cycle calculation (quarterly data)
No. days
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||
| Average inventory processing period | 201 | 199 | 196 | 201 | 199 | 198 | 200 | 208 | 201 | 193 | 186 | 183 | 166 | 162 | 161 | 155 | 139 | 130 | ||||||
| Average receivable collection period | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Average payables payment period | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||
| Cash conversion cycle1 | 228 | 220 | 224 | 216 | 218 | 214 | 228 | 230 | 226 | 220 | 215 | 203 | 183 | 187 | 190 | 176 | 161 | 161 | ||||||
| Benchmarks | ||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||
| Abbott Laboratories | 112 | 108 | 108 | 117 | 118 | 111 | 99 | 118 | 114 | 114 | 106 | 114 | 110 | 103 | 82 | 82 | 85 | 77 | ||||||
| Medtronic PLC | 175 | 169 | 166 | 173 | 167 | 167 | 161 | 189 | 186 | 183 | 159 | 182 | 171 | 157 | 148 | 153 | 149 | 147 | ||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 201 + 55 – 28 = 228
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a significant upward trend over the analyzed period, indicating a lengthening of the time required to convert resource investments into cash. This expansion is primarily driven by a substantial increase in the inventory processing period, while receivable collections and payables payments have remained relatively stable.
- Average Inventory Processing Period
- A consistent and marked increase is observed, rising from 130 days in March 2022 to a peak of 208 days in September 2024. Following this peak, the period stabilized, fluctuating between 196 and 201 days through June 2026. This trend indicates a decelerating inventory turnover rate or a strategic increase in held stock.
- Average Receivable Collection Period
- The collection period demonstrates relative stability, generally fluctuating within a narrow range between 48 and 58 days. The absence of a clear long-term trend suggests that the efficiency of credit and collection processes has remained consistent throughout the period.
- Average Payables Payment Period
- Payment durations show minor fluctuations, ranging from a minimum of 25 days to a maximum of 35 days. Although slight intermittent increases occurred between 2023 and 2025, the overall duration remains low, providing minimal offset to the increasing inventory holding time.
- Cash Conversion Cycle
- The overall cycle expanded from 161 days in early 2022 to a peak of 230 days in September 2024, eventually settling at 228 days by June 2026. Because the receivable and payable components remained largely constant, the expansion of the cash conversion cycle is directly attributable to the extended inventory processing duration.
AI Ask an analyst for more